Intellia Therapeutics
NTLA
165 hedge funds and large institutions have $1.12B invested in Intellia Therapeutics in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 69 increasing their positions, 33 reducing their positions, and 25 closing their positions.
109% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 33
101% more call options, than puts
Call options by funds: $3.84M | Put options by funds: $1.92M
1.32% more ownership
Funds ownership: 94.85% → 96.17% (+1.3%)
4% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 25
1% more funds holding
Funds holding: 164 → 165 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $1.13B → $1.12B (-$11.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$15.4M |
| 2 |
BlackRock
New York
|
+$12.4M |
| 3 |
Goldman Sachs
New York
|
+$8.64M |
| 4 |
Morgan Stanley
New York
|
+$8.48M |
| 5 |
Millennium Management
New York
|
+$6.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$8.79M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.79M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.54M |
| 4 |
O
OrbiMed
New York
|
-$2.88M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$2.77M |
NTLA Hedge Fund Activity: Q3 2020 in Review
165 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2020, worth a combined $1.12B — down 1% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new NTLA positions and 25 closed out — a net gain of 1 holder — while 69 added to existing stakes and 33 trimmed.
The largest buyer was State Street, adding an estimated $15.4M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $8.79M sold.
- 165 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2020, up from 164 in Q2 2020.
- Funds reported $1.12B of Intellia Therapeutics stock for Q3 2020, down 1% quarter-over-quarter.
- 26 funds opened new Intellia Therapeutics positions in Q3 2020 and 25 closed out, a net change of +1 holder.
- The largest Intellia Therapeutics buyer in Q3 2020 was State Street, an estimated $15.4M added.
- The largest Intellia Therapeutics seller in Q3 2020 was Avidity Partners Management, an estimated $8.79M sold.
Based on aggregated 13F filings for Q3 2020.